Quest Diagnostics Incorporated (DGX)
USD 163.98
(0.08%)
USD 163.98
(0.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.73 Billion USD | -1.1% |
| 2022 | 1.82 Billion USD | -42.69% |
| 2021 | 3.15 Billion USD | 31.15% |
| 2020 | 2.41 Billion USD | 52.41% |
| 2019 | 1.58 Billion USD | 12.38% |
| 2018 | 1.4 Billion USD | -3.1% |
| 2017 | 1.45 Billion USD | 6.69% |
| 2016 | 1.47 Billion USD | -12.82% |
| 2015 | 1.55 Billion USD | 17.56% |
| 2014 | 1.3 Billion USD | 0.84% |
| 2013 | 1.79 Billion USD | -13.4% |
| 2012 | 1.52 Billion USD | 16.44% |
| 2011 | 1.3 Billion USD | -17.35% |
| 2010 | 1.58 Billion USD | -4.24% |
| 2009 | 1.63 Billion USD | 7.06% |
| 2008 | 1.5 Billion USD | 15.54% |
| 2007 | 1.32 Billion USD | -0.01% |
| 2006 | 1.32 Billion USD | 14.27% |
| 2005 | 1.18 Billion USD | 8.02% |
| 2004 | 1.04 Billion USD | 14.07% |
| 2003 | 950.35 Million USD | 34.26% |
| 2002 | 723.84 Million USD | 26.54% |
| 2001 | 559.11 Million USD | 22.28% |
| 2000 | 452.11 Million USD | 42.99% |
| 1999 | 242.8 Million USD | 87.42% |
| 1998 | 163.1 Million USD | -16.58% |
| 1997 | 151.1 Million USD | 140.6% |
| 1996 | -502.18 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 487 Million USD | 10.9% |
| 2024 Q1 | 435 Million USD | 9.95% |
| 2024 Q3 | 479 Million USD | 0.21% |
| 2023 Q2 | 466 Million USD | 11.22% |
| 2023 FY | - USD | -1.1% |
| 2023 Q1 | 419 Million USD | 63.04% |
| 2023 Q3 | 450 Million USD | -3.43% |
| 2023 Q4 | 420 Million USD | -6.67% |
| 2022 Q4 | 257 Million USD | -47.76% |
| 2022 FY | - USD | -42.69% |
| 2022 Q3 | 492 Million USD | 5.58% |
| 2022 Q2 | 466 Million USD | -21.68% |
| 2022 Q1 | 595 Million USD | -7.75% |
| 2021 FY | - USD | 31.15% |
| 2021 Q1 | 765 Million USD | -14.53% |
| 2021 Q2 | 955 Million USD | 24.84% |
| 2021 Q3 | 793 Million USD | -16.96% |
| 2021 Q4 | 645 Million USD | -18.66% |
| 2020 Q4 | 895 Million USD | 1.24% |
| 2020 Q3 | 884 Million USD | 129.61% |
| 2020 Q2 | 385 Million USD | 57.79% |
| 2020 Q1 | 244 Million USD | -46.02% |
| 2020 FY | - USD | 52.41% |
| 2019 FY | - USD | 12.38% |
| 2019 Q1 | 341 Million USD | 15.59% |
| 2019 Q2 | 391 Million USD | 14.66% |
| 2019 Q4 | 452 Million USD | 14.14% |
| 2019 Q3 | 396 Million USD | 1.28% |
| 2018 Q3 | 384 Million USD | 0.26% |
| 2018 FY | - USD | -3.1% |
| 2018 Q1 | 344 Million USD | -0.58% |
| 2018 Q2 | 383 Million USD | 11.34% |
| 2018 Q4 | 295 Million USD | -23.18% |
| 2017 Q4 | 346 Million USD | 9.84% |
| 2017 Q3 | 315 Million USD | -20.45% |
| 2017 FY | - USD | 6.69% |
| 2017 Q2 | 396 Million USD | 15.12% |
| 2017 Q1 | 344 Million USD | 0.88% |
| 2016 Q3 | 389 Million USD | 8.06% |
| 2016 Q1 | 270 Million USD | -14.56% |
| 2016 FY | - USD | -12.82% |
| 2016 Q4 | 341 Million USD | -12.34% |
| 2016 Q2 | 360 Million USD | 33.33% |
| 2015 Q1 | 235 Million USD | -31.69% |
| 2015 FY | - USD | 17.56% |
| 2015 Q4 | 316 Million USD | -55.11% |
| 2015 Q3 | 704 Million USD | 120.69% |
| 2015 Q2 | 319 Million USD | 35.74% |
| 2014 Q3 | 341 Million USD | -3.13% |
| 2014 Q4 | 344 Million USD | 0.88% |
| 2014 FY | - USD | 0.84% |
| 2014 Q1 | 290 Million USD | -16.91% |
| 2014 Q2 | 352 Million USD | 21.38% |
| 2013 Q4 | 349 Million USD | 19.4% |
| 2013 Q3 | 292.3 Million USD | -20.59% |
| 2013 FY | - USD | -13.4% |
| 2013 Q2 | 368.1 Million USD | 20.02% |
| 2013 Q1 | 306.7 Million USD | -10.56% |
| 2012 FY | - USD | 16.44% |
| 2012 Q1 | 379.4 Million USD | -6.1% |
| 2012 Q3 | 377.5 Million USD | -8.79% |
| 2012 Q4 | 342.9 Million USD | -9.17% |
| 2012 Q2 | 413.9 Million USD | 9.09% |
| 2011 Q4 | 404.05 Million USD | 1.47% |
| 2011 FY | - USD | -17.35% |
| 2011 Q1 | 328.2 Million USD | -10.09% |
| 2011 Q2 | 397.4 Million USD | 21.08% |
| 2011 Q3 | 398.2 Million USD | 0.2% |
| 2010 Q4 | 365.03 Million USD | -8.21% |
| 2010 FY | - USD | -4.24% |
| 2010 Q1 | 369.9 Million USD | -7.84% |
| 2010 Q2 | 436 Million USD | 17.87% |
| 2010 Q3 | 397.7 Million USD | -8.78% |
| 2009 Q3 | 366.1 Million USD | -15.46% |
| 2009 FY | - USD | 7.06% |
| 2009 Q4 | 401.37 Million USD | 9.64% |
| 2009 Q1 | 394.92 Million USD | 5.5% |
| 2009 Q2 | 433.05 Million USD | 9.65% |
| 2008 Q4 | 374.34 Million USD | -5.25% |
| 2008 Q1 | 346.55 Million USD | -9.4% |
| 2008 Q2 | 373.34 Million USD | 7.73% |
| 2008 Q3 | 395.06 Million USD | 5.82% |
| 2008 FY | - USD | 15.54% |
| 2007 FY | - USD | -0.01% |
| 2007 Q2 | 326.52 Million USD | 31.03% |
| 2007 Q3 | 370.73 Million USD | 13.54% |
| 2007 Q1 | 249.19 Million USD | -20.28% |
| 2007 Q4 | 382.5 Million USD | 3.17% |
| 2006 Q4 | 312.58 Million USD | -9.27% |
| 2006 Q1 | 303.51 Million USD | 5.05% |
| 2006 Q2 | 324.87 Million USD | 7.04% |
| 2006 Q3 | 344.54 Million USD | 6.05% |
| 2006 FY | - USD | 14.27% |
| 2005 Q2 | 304.74 Million USD | 12.08% |
| 2005 FY | - USD | 8.02% |
| 2005 Q4 | 288.92 Million USD | -3.77% |
| 2005 Q1 | 271.89 Million USD | -0.29% |
| 2005 Q3 | 300.25 Million USD | -1.47% |
| 2004 Q1 | 248.72 Million USD | 5.23% |
| 2004 FY | - USD | 14.07% |
| 2004 Q2 | 274.08 Million USD | 10.2% |
| 2004 Q3 | 274.09 Million USD | 0.0% |
| 2004 Q4 | 272.7 Million USD | -0.51% |
| 2003 FY | - USD | 34.26% |
| 2003 Q4 | 236.38 Million USD | -7.01% |
| 2003 Q3 | 256.05 Million USD | 1.28% |
| 2003 Q2 | 256.95 Million USD | 27.29% |
| 2003 Q1 | 200.17 Million USD | 14.66% |
| 2002 Q2 | 193.17 Million USD | 18.56% |
| 2002 Q1 | 158.77 Million USD | 14.04% |
| 2002 Q3 | 191.91 Million USD | 0.13% |
| 2002 Q4 | 179.98 Million USD | -8.42% |
| 2002 FY | - USD | 26.54% |
| 2001 FY | - USD | 22.28% |
| 2001 Q4 | 142.81 Million USD | -0.79% |
| 2001 Q3 | 142.23 Million USD | -9.69% |
| 2001 Q2 | 150.22 Million USD | 14.45% |
| 2001 Q1 | 123.85 Million USD | 36.39% |
| 2000 FY | - USD | 42.99% |
| 2000 Q4 | 92.4 Million USD | -18.71% |
| 2000 Q3 | 124.78 Million USD | -9.83% |
| 2000 Q1 | 99.85 Million USD | -22.14% |
| 2000 Q2 | 135.06 Million USD | 36.07% |
| 1999 Q2 | 48.15 Million USD | 23.7% |
| 1999 Q1 | 39.22 Million USD | -5.81% |
| 1999 Q4 | 86.5 Million USD | 27.06% |
| 1999 FY | - USD | 87.42% |
| 1999 Q3 | 69 Million USD | 100.6% |
| 1998 Q3 | 38.7 Million USD | -10.96% |
| 1998 Q4 | 38.5 Million USD | 8.04% |
| 1998 FY | - USD | -16.58% |
| 1998 Q2 | 44.6 Million USD | 4.93% |
| 1998 Q1 | 41.4 Million USD | -45.1% |
| 1997 Q2 | 47.2 Million USD | 27.03% |
| 1997 Q4 | 27.7 Million USD | 95.96% |
| 1997 FY | - USD | 140.6% |
| 1997 Q1 | 38.4 Million USD | 108.19% |
| 1997 Q3 | 37.6 Million USD | -18.18% |
| 1996 Q4 | -465.2 Million USD | -194.62% |
| 1996 Q3 | -157.9 Million USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Agilent Technologies, Inc. | 1.67 Billion USD | -3.28% |
| Charles River Laboratories International, Inc. | 1.03 Billion USD | -67.81% |
| Danaher Corporation | 7.54 Billion USD | 77.05% |
| Enzo Biochem, Inc. | -8.34 Million USD | 20847.484% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 46.806% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | -28.353% |
| Mettler-Toledo International Inc. | 1.18 Billion USD | -46.388% |
| Qiagen N.V. | 650.58 Million USD | -166.223% |
| Revvity, Inc. | 813.25 Million USD | -112.972% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 83.963% |
| Waters Corporation | 1.02 Billion USD | -69.43% |